المؤلفون: Álvarez E; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.; CIBERCV, Madrid, Spain., Paradela-Dobarro B; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.; CIBERCV, Madrid, Spain., Raposeiras-Roubín S; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.; Servicio de Cardiología y Unidad de Hemodinámica, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain., González-Juanatey JR; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.; CIBERCV, Madrid, Spain.; Servicio de Cardiología y Unidad de Hemodinámica, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.

المصدر: British journal of clinical pharmacology [Br J Clin Pharmacol] 2018 Feb; Vol. 84 (2), pp. 280-291. Date of Electronic Publication: 2017 Oct 25.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Endothelium, Vascular/*drug effects , Factor Xa Inhibitors/*pharmacology , Fibrinolytic Agents/*pharmacology , Protective Agents/*pharmacology , Rivaroxaban/*pharmacology, Cell Movement/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Factor Xa Inhibitors/administration & dosage ; Fibrinolytic Agents/administration & dosage ; Human Umbilical Vein Endothelial Cells ; Humans ; Matrix Metalloproteinase 2/genetics ; Protective Agents/administration & dosage ; Rivaroxaban/administration & dosage ; Transcriptome/drug effects ; Urokinase-Type Plasminogen Activator/genetics